Recently, Dey et al. demonstrated a significant correlation of NLR with PASI under anti-TNF-α (adalimumab, etanercept), anti-IL-12/23 (ustekinumab), or anti-IL-17A (secukinumab, ixekizumab) therapy in 316 psoriasis patients [29]. This evidence concerns the gene IL17A and psoriasis.